Abstract
INTRODUCTION
Cardiovascular disease is a major public health problem worldwide, even in the United States of America, and it accounts for approximately 30 % of all deaths [1] . Cardiovascular disease has also been considered to be the major cause of death in the Kingdom of Saudi Arabia [2] . Due to increasing prevalence of cardiovascular disease in children, researchers have recommended the establishment of well-equipped hospitals to for the care of children with cardiovascular disease in developing countries as well as in Kingdom of Saudi Arabia [3] . Studies have also revealed that there is a need for more research in the field of cardiovascular disease in developing countries because of the likelihood of prevalence of cardiovascular disease in all age groups in these countries [4, 5] .
There are many cardio-active derivatives of 6-(4-aminophenyl)-4,5-dihydro-3(2H)-pyridazinone containing 6-(4-aminophenyl)-4,5-dihydro-3(2H)-pyridazinone moiety (1) Some reviews on pyridazinone derivatives have been published [22] [23] [24] [25] . However, these reviews are directed towards the general chemistry and general biological activities of diverse pyridazine derivatives. None of these articles focused on the use of any specific chemical moiety for the development of cardio-active agents.
The current review gives an insight on the potential of 6-(4-aminophenyl)-4,5-dihydro-3(2H)-pyridazinone moiety for the development of cardio-active agents, and briefly discusses relevant literature related to the synthesis and use of this chemical for the preparation of cardioactive agents. Accordingly, literature references wherein 6-(4-aminophenyl)-4,5-dihydro-3(2H)-pyridazinone moiety was not synthesized and/or not used for the preparation of cardio-active agents were excluded. 
6-(4-AMINOPHENYL)-4,5-DIHYDRO-3(2H)-PYRIDAZINONE DERIVATIVES AS CARDIOACTIVE AGENTS
6-(4-Aminophenyl)-4,5-dihydro-3(2H)-pyridazinone (1) was first reported in 1967 by Gerhard and August [26] . Gerhard and August also reported that this compound is associated with anti-inflammatory and sustained blood pressure reducing activities [27] .
Curran and Ross [28] prepared and tested a series of 6-phenyl-4,5-dihydro-3(2H)-pyridazinones. They concluded that the potent and most active hypotensive agents (2) in normotensive rats were derivatives with acetamido and cyano groups in the para or meta position of the benzene ring, combined with 5-methyl substituent in the hetero ring.
Thyes et al [29] prepared 6-Aryl-4,5-dihydro-3(2H)-pyridazinones which exhibited aggregation-inhibiting activity on human platelets in vitro and on rat platelets ex vivo, as well as a hypotensive action on rats. The strongest pharmacological effects were found with dihydropyridazinones that have R = chloroalkanoyl substituent, together with a methyl group in the 5-position (3). The hypotensive actions of these compounds were 40 times higher than that of dihydralazine.
These authors further demonstrated that the para-substituted compounds had a strong inhibiting effect on collagen-induced and ADPinduced aggregation of human platelets. It is known that platelet aggregation plays an important role in the pathogenesis of cardiovascular disease [30] .
The in vitro human platelet aggregation and the ex vivo rat platelet aggregation-inhibiting activities of 6-aryl-4,5-dihydropyridazinones (4) with R 1 = R 2 = R 4 = Me or H; and R 3 = amine containing, groups were correlated with the van der Waals volume (Vw) of R 3 by Gupta et al [31] . Their results suggested that the size of the substituent on the aryl group plays an important role in the inhibition of platelet aggregation in this series of compounds. Based on the correlating equations obtained, it was further suggested that the inhibition of platelet aggregation most likely involved hydrophobic interaction. A moderate correlation existed between the hypotensive activity of these drugs in rats and Vw, indicating that hypotensive activity also was partly affected by the size of the substituent on the aryl group. Although it was assumed that hydrophobic interactions also played some role in the hypotensive action, it was argued, based on the results, that platelet aggregation inhibition and hypotensive activity involved two different receptor sites. [32] . Most members of this series produced dose-related increases in myocardial contractility that were associated with relative minor increase in heart rate and decrease in systemic arterial blood pressure. Among the synthesized compounds (5), the one with R = H (CI-914) and R = Methyl (CI-930) were more potent than amrinone and milrinone, respectively. It was also postulated that the positive inotropic effect of these compounds was due to the inhibition of cardiac phosphodiesterase fraction III, rather than the stimulation of β-adrenergic receptors. 
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Okushima et al [33] reported pyridazinone derivatives with cardiac activity. These pyridazinones, with R = H and Me; R 1 = 4-pyridyl, 2-pyridyl, 2-pyrimidyl and 4-quinolyl, were evaluated for inotropic activities in vitro and for cardio-hemodynamic effects in vivo. The hydrochloride salts of compound (6) with R = H (MCI-154) or Me and R 1 = 4-pyridyl showed extremely potent positive inotropic and vasodilating activities, and good ED 50 relative to amrinone. 
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Slater et al [35] reported the design and synthesis of a series of combined vasodilator-β-adrenoceptor antagonists based on 6-arylpyridazinones, and evaluated them as vasodilator-β-adrenoceptor antagonists and potential antihypertensive agents. Many of the synthesized compounds showed high level of intrinsic sympathomimetic activities (ISA) and relatively short durations of action. Di-substitution in the 2,3-positions or in the 4-position of the aryloxy ring produced compounds with low ISA levels and, in some cases, improved duration of action. The 5-methylpyridazinone derivatives displayed more antihypertensive activity than their 5-H homologs. The compound, SK&F 95018, was selected for further development.
Benzodioxane pyridazinones (8) and benzodioxane dihydropyridazinone (9) have been reported as antihypertensive agents by Stefano et al [36] . Derivatives with Z = 1,4-disubstituted piperazine showed good hypotensive activities, which were related to anti-adrenergic effects.
Alfred et al [37] have reported 4,5-dihydro-6-(1H-indol-5-yl)-pyridazin-3(2H)-ones and related compounds with positive inotropic activities. Most of these compounds produced increases in myocardial contractility with little effects on heart rate and blood pressure. The cardiotonic effect of compound (10) was at least 2-fold higher than that of pimobendan following oral administration.
It has been suggested that, for optimal cardiotonic activity within this class of indole derivatives, a heterocyclic aromatic ring in position 2, a hydrogen or a Me group in position 3 and a dihydropyridazinone ring system in position 5 of the indole are necessary. [38] . The study revealed that the structure-activity relationships of the tricyclic pyridazinones differ from those of bicyclic pyridazinones mainly in respect of the effect produced by introducing a methyl group in the pyridazinone ring. Introduction of a 5-methyl group has been widely reported to lead to compounds of significantly greater potencies in the 4,5-dihydro-6-phenylpyridazin-3(2H)-ones. On the other hand, the tricyclic 4a-methylpyridazinones showed similar levels of inotropic, vasodilator and PDE III inhibitory potencies to their normethyl analogues. In this series of compounds, the tricyclic 4a-methylpyridazinones (11) with R = cyano, CONH2, NH2, NHAc, or OMe, and n = 1,2, …., showed good inotropic, vasodilator and PDE III inhibitory potencies. The synthesis and platelet aggregation-inhibitory activities of 6-(4-substituted acylamidophenyl)-4,5-dihydro-3(2H)-pyridazinones and 6-(4-substituted acylaminophenyl)-4,5-dihydro-3(2H)-pyridazonones have been described by Liu et al [43, 44] . Preliminary pharmacological tests revealed that all the synthesized compounds inhibited appreciable ADP-induced platelet aggregation activities in rabbits. Liu et al [45] have further reported synthesis of 6-(4-substituted acylaminophenyl)-4,5-dihydro-3(2H)-pyridazinones and their inhibitory actions on platelet aggregation. These compounds were synthesized based on structure-activity relationships of anti-platelet aggregation of dihydropyridazinones.
The synthesized compounds showed different levels of inhibitory activities on ADP induced-platelet aggregation. Synthesis of 6-(4-(substituted amino) phenyl)-4,5-dihydropyridazin-3(2H)-ones as potential positive inotropic agents has been described by Abou-Zeid et al [46] . Some of the synthesized compounds exhibited good positive inotropic effects. 
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The anti-platelet aggregation activities of 6-(4-substituted acetamido phenyl)-4,5-dihydro-3(2H)-pyridazinones derived from different piperazine groups have been studied by Xu et al [56] . All the synthesized compounds had potent anti-platelet aggregation activities. It was also found that antiaggregation activity was influenced by the carbon chain length of the 4-substituted piperazine Wang et al [21] has designed, synthesized and studied the structure-activity relationships of 6-phenyl-4,5-dihydro-3(2H)-pyridazinone derivatives with respect to their cardiotonic properties. Among these compounds, 2,3-dichloro-N-(4-(4-methyl-6-oxo-1,4,5,6-tetrahydropyridazin-3-yl)phenyl) benzamide (22), 4-amino-3-methyl-N-(4-(4-methyl-6-oxo-1,4,5,6-tetrahydropyridazin-3-yl)phenyl) benzamide (23), 3-methyl-4-nitro-N-(4-(6-oxo-1,4,5,6-tetrahydropyridazin-3-yl)phenyl) benzamide (24) and 4-amino-3-methyl-N-(4-(6-oxo-1,4,5,6-tetrahydropyridazin-3-yl) phenyl) benzamide (25) exhibited cardiotonic activities which were comparable to that of levosimendan. (28), where R = alkyl, alkylamine, alkanoylamine or alkoxy group; R 1 = alkyl, acetyl, COOEt, CN; and RR 1 = five membered heterocycle. The cardiotonic, hypotensive, and platelet-aggregation inhibition activities were also investigated. Results from in vitro studies of their positive inotropic effects on isolated rabbit heart revealed that twelve of the compounds exhibited higher effective responses than digoxin, while nine compounds were comparable to digoxin in their responses. However eight of the compounds were less active than digoxin. 
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CONCLUSION
